Last updated: February 15, 2026
Overview
The drug identified by NDC 51407-0051 is a specific formulation marketed under the brand names Xyrem (sodium oxybate). Xyrem is primarily prescribed for narcolepsy and cataplexy and is a Schedule III controlled substance in the United States. Its market dynamics are influenced by regulations, patent status, manufacturing costs, and competition from alternative therapies.
Market Size and Scope
Target Conditions:
- Narcolepsy: Incidence approximately 0.025-0.05% globally, with higher prevalence in the U.S (approximately 135 per 100,000).
- Cataplexy: Occurs in about 70% of narcolepsy patients.
Patient Population:
- U.S. market estimate: Approximately 200,000-300,000 diagnosed patients.
- Market penetration: Estimated initial usage rate around 40-60%, with ongoing growth encouraged by expanded diagnostic criteria.
Sales Data:
- Global annual sales (2022): Approximately $1.1 billion based on IQVIA data.
- U.S. market share: Represents roughly 80-85% of global sales due to higher diagnosis rates and access.
Regulatory and Patent Landscape
Patent Status:
- The original patent for Xyrem expired in 2017.
- The drug remains protected via the Orphan Drug Act, extending exclusivity until 2027-2029.
- Competing formulations or generics have begun entering the market post-patent expiry, especially in the EU and select U.S. states, but the drug retains brand dominance due to regulatory barriers and established prescriber familiarity.
Regulatory Restrictions:
- Strict control due to abuse potential.
- Distribution channels are tightly regulated through REMS programs.
Market Dynamics
Competitive Landscape:
- Off-label and alternative therapies: Modafinil, armodafinil, sodium oxybate-like compounds, behavioral therapies.
- Generic Entry: Post-patent expiration, generics are expected to enter and erode market share. However, limited due to administration complexities and REMS restrictions.
Pricing Environment:
- Brand Name: Average wholesale price (AWP) in U.S. around $22,000-$24,000 per year per patient.
- Generics: Expected at discounts of 20-40%, but uptake varies due to prescriber and patient preferences.
Distribution and Reimbursement:
- Insurance coverage is widespread; Medicaid and Medicare have strict formulary controls favoring generics and cost-effective options.
- Managed care organizations negotiate rebates and discounts, reducing net prices.
Price Projections (Next 5 Years)
| Year |
Estimated Average Wholesale Price (AWP) |
Estimates and Assumptions |
| 2023 |
$23,000 |
Stable, barring regulatory or market changes. |
| 2024 |
$22,500 |
Slight decline as generics gain market share. |
| 2025 |
$21,000 |
Deeper penetration of generics; potential price reductions. |
| 2026 |
$19,500 |
Increased competition and payer pressure. |
| 2027 |
$18,000 |
Anticipated generic dominance; further discounts possible. |
Key drivers:
- Patent expiration impacts pricing; generics will exert downward pressure.
- Market expansion driven by increased diagnosis and awareness.
- Managed care negotiations and rebates will continue to influence net prices.
Risks and Opportunities
Risks:
- Accelerated generic entry could lower prices more rapidly.
- Regulatory or safety concerns may influence prescribing patterns.
- Emerging drugs, possibly with less abuse potential, could shift market share.
Opportunities:
- Market expansion through off-label uses or new indications.
- Development of abuse-deterrent formulations or improved delivery systems.
- Expansion into global markets with unmet needs.
Key Takeaways
- The current global market size for NDC 51407-0051 (Xyrem) is roughly $1.1 billion annually.
- Patents and regulatory exclusivity protect current sales until around 2027-2029.
- U.S. average wholesale prices are approximately $23,000 per year; expect gradual declines due to generics commencing post-patent expiry.
- Price projections forecast a decline to roughly $18,000 by 2027, with significant influence from generics and payer strategies.
- The market remains highly regulated, with sale dynamics driven by safety concerns and prescriber behavior.
FAQs
1. What factors could accelerate pricing declines for NDC 51407-0051?
Entry of generic equivalents and increased formulary restrictions will reduce prices more swiftly. Regulatory changes or safety concerns could also impact pricing.
2. How do regulatory restrictions impact market penetration?
REMS programs and controlled distribution channels limit access, maintaining brand loyalty and hindering generic market share.
3. What is the potential for growth outside the U.S.?
Markets like Europe and Asia present growth opportunities, but they face different regulatory and reimbursement environments.
4. Can new formulations or delivery methods extend market viability?
Yes, abuse-deterrent formulations that preserve efficacy could sustain higher prices and market share.
5. How does patent expiration influence strategic planning?
Generics entering early could erode margins; companies should consider pipeline development, alternative indications, or value-added formulations.
Sources
- IQVIA. (2022). National Prescription Audit.
- FDA. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
- Statista. (2022). Narcolepsy market estimates.
- MarketWatch. (2023). Price trends for sodium oxybate.
- U.S. Patent Office. (2022). Patent status for Xyrem-related patents.
[Note: All data are approximate and should be verified with latest market intelligence and regulatory filings.]
